ASXL2 and pancreatic adenocarcinoma: The results showed that the level of TIDE score in the high ASXL2 expression group was lower than that in the low ASXL2 expression group, which indicated that PAAD patients with high ASXL2 expression levels were more likely to respond to ICB (Figure 4B).